BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25621804)

  • 1. Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
    Lawitschka A; Faraci M; Yaniv I; Veys P; Bader P; Wachowiak J; Socie G; Aljurf MD; Arat M; Boelens JJ; Duarte R; Tichelli A; Peters C
    Bone Marrow Transplant; 2015 Apr; 50(4):592-7. PubMed ID: 25621804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Wachowiak J; Sykora KW; Cornish J; Chybicka A; Kowalczyk JR; Gorczyńska E; Choma M; Grund G; Peters C;
    Bone Marrow Transplant; 2011 Dec; 46(12):1510-8. PubMed ID: 21297673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
    Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience.
    Beier R; Schulz A; Hönig M; Eyrich M; Schlegel PG; Holter W; Stachel KD; Ehlert K; Greil J; Nürnberger W; Wössmann W; Bader P; Urban C; Müller I; Suttorp M; Sauer M; Gruhn B; Meisel R; Zimmermann M; Sykora KW
    Bone Marrow Transplant; 2013 Apr; 48(4):491-501. PubMed ID: 23085832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
    Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
    Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
    Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
    Cable C; Buzzeo MP; Schold JD; Khan S; Leather H; Moreb J; Jamieson K; Scornik J; Amdur RJ; Wingard JR; Reddy V
    Bone Marrow Transplant; 2010 Jan; 45(1):31-7. PubMed ID: 19543325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
    Takahata M; Hashino S; Okada K; Onozawa M; Kahata K; Sugita J; Shigematsu A; Kondo T; Yamamoto S; Endo T; Nishio M; Ito YM; Tanaka J; Koike T; Asaka M; Imamura M
    Am J Hematol; 2010 Apr; 85(4):243-8. PubMed ID: 20162540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
    Ussowicz M
    Drugs Today (Barc); 2020 Jun; 56(6):389-403. PubMed ID: 32525137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
    Wang FR; Huang XJ; Liu DH; Chen H; Wang Y; Tang FF; Sun YQ; Fu HX; Liu KY; Xu LP
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1028-32. PubMed ID: 24503400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
    Yoshida T; Kusumoto S; Masuda A; Totani H; Narita T; Masaki A; Ito A; Ri M; Ishida T; Komatsu H; Iida S
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):719-24. PubMed ID: 26199244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.